Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.
Loading...
Files
Embargo End Date
ICR Authors
Authors
Dowling, RJO
Sparano, JA
Goodwin, PJ
Bidard, F-C
Cescon, DW
Chandarlapaty, S
Deasy, JO
Dowsett, M
Gray, RJ
Henry, NL
Meric-Bernstam, F
Perlmutter, J
Sledge, GW
Thorat, MA
Bratman, SV
Carey, LA
Chang, MC
DeMichele, A
Ennis, M
Jerzak, KJ
Korde, LA
Lohmann, AE
Mamounas, EP
Parulekar, WR
Regan, MM
Schramek, D
Stambolic, V
Whelan, TJ
Wolff, AC
Woodgett, JR
Kalinsky, K
Hayes, DF
Sparano, JA
Goodwin, PJ
Bidard, F-C
Cescon, DW
Chandarlapaty, S
Deasy, JO
Dowsett, M
Gray, RJ
Henry, NL
Meric-Bernstam, F
Perlmutter, J
Sledge, GW
Thorat, MA
Bratman, SV
Carey, LA
Chang, MC
DeMichele, A
Ennis, M
Jerzak, KJ
Korde, LA
Lohmann, AE
Mamounas, EP
Parulekar, WR
Regan, MM
Schramek, D
Stambolic, V
Whelan, TJ
Wolff, AC
Woodgett, JR
Kalinsky, K
Hayes, DF
Document Type
Journal Article
Date
2019-12-04
Date Accepted
2019-07-08
Abstract
Late disease recurrence (more than 5 years after initial diagnosis) represents a clinical challenge in the treatment and management of estrogen receptor-positive breast cancer (BC). An international workshop was convened in Toronto, Canada, in February 2018 to review the current understanding of late recurrence and to identify critical issues that require future study. The underlying biological causes of late recurrence are complex, with the processes governing cancer cell dormancy, including immunosurveillance, cell proliferation, angiogenesis, and cellular stemness, being integral to disease progression. These critical processes are described herein as well as their role in influencing risk of recurrence. Moreover, observational and interventional clinical trials are proposed, with a focus on methods to identify patients at risk of recurrence and possible strategies to combat this in patients with estrogen receptor-positive BC. Because the problem of late BC recurrence of great importance, recent advances in disease detection and patient monitoring should be incorporated into novel clinical trials to evaluate approaches to enhance patient management. Indeed, future research on these issues is planned and will offer new options for effective late recurrence treatment and prevention strategies.
Citation
JNCI cancer spectrum, 2019, 3 (4), pp. pkz049 - ?
Source Title
Publisher
OXFORD UNIV PRESS
ISSN
2515-5091
eISSN
2515-5091
Collections
Research Team
Endocrinology